BPC-157 + TB-500 – Wolverine Stack (5MG+5MG)

Description

This is a dual-peptide research formulation combining BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). Both peptides have been independently characterized in the preclinical literature; this formulation supplies both in a single lyophilized vial for in vitro research applications requiring simultaneous investigation of their complementary signalling pathways.

Molecular Profile
Components: BPC-157 (CAS 137525-51-0) + TB-500 (CAS 77591-33-4)
BPC-157 Molecular Weight: 1,419.55 Da
TB-500 Molecular Weight: 4,963.44 Da
Format: Lyophilized white powder
Storage: -20°C, desiccated
Reconstitution: Sterile bacteriostatic water

Research Context
BPC-157 (sequence: GEPPPGKPADDAGLV) is a 15-amino acid gastric juice–derived peptide with well-documented in vitro utility in angiogenesis, nitric oxide pathway modulation, and fibroblast migration research. TB-500 is a synthetic analogue of the Thymosin Beta-4 active fragment (Ac-LKKTETQ), documented in the literature for its role in actin sequestration, endothelial cell migration, and connective tissue repair signalling. Together, these two peptides provide complementary in vitro research coverage of vascular biology and cytoprotective signalling pathways.

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.